Can deep brain stimulation effectively treat severe depression?

How well does DBS actually work for severe depression?

Deep brain stimulation (DBS) shows strong promise for treatment-resistant depression (TRD), with average response rates around 60% across different brain targets [6]. This means that about 6 out of 10 patients who have not benefited from medications or therapy see significant improvement. In one of the most successful studies, targeting the subcallosal cingulate (SCC) region, 90% of participants responded and 70% achieved full remission after 24 weeks of stimulation [3]. Another study targeting the habenula (HB) found depression and anxiety symptoms reduced by 49% after one month, with improvements largely maintained for up to a year [1]. These numbers are encouraging, but they come from small studies (7-30 patients), so results may vary in larger populations.

However, not everyone responds. In the habenula study, one patient experienced a severe manic episode requiring hospitalization, and dropout rates were high [1]. A study of subcallosal cingulate DBS found that only about half of patients responded, and brain network features—like how well different regions communicate—predicted who would benefit [2]. This variability means DBS is not a one-size-fits-all solution; it works best when tailored to the individual's brain circuitry.

What are the risks and side effects?

DBS is brain surgery, so it carries risks like infection, bleeding, and complications from anesthesia. Beyond surgical risks, psychiatric side effects can occur. In a study of habenula DBS, one patient developed an acute manic episode two months after surgery that required hospitalization [1]. However, the same study found that two patients with mild hypomania at baseline actually saw sustained improvement in mania symptoms after DBS, suggesting effects depend on the individual. Importantly, a long-term study of medial forebrain bundle DBS found no changes in personality traits like extraversion or openness over 5 years, indicating that DBS does not fundamentally alter who you are [4].

Stimulation adjustments can also cause temporary mood swings or discomfort. Because DBS requires trial-and-error programming, patients may need frequent visits to fine-tune settings. Newer devices that record brain activity in real time may help reduce this guesswork, as seen in a study where a personalized biomarker guided adjustments and led to remission [5].

Who is most likely to benefit from DBS?

DBS is typically reserved for people with treatment-resistant depression (TRD)—those who have not improved after multiple medications, therapy, or electroconvulsive therapy. The best candidates appear to have specific brain network patterns. For example, a study using EEG before surgery found that patients with lower brain network integration and higher activity in the anterior cingulate cortex were more likely to respond to subcallosal cingulate DBS [2]. Another study showed that a biomarker derived from local field potentials (brain electrical signals) could accurately track recovery and predict who would benefit [3].

Additionally, the serotonin system may play a role. A study using auditory evoked potentials found that baseline serotonin activity predicted response to subcallosal cingulate DBS, similar to how it predicts response to SSRI antidepressants [7]. This suggests that DBS may work partly by boosting serotonin, so patients with low serotonin activity might respond better. However, these biomarkers are still experimental and not yet used in routine clinical practice.

Sources used in this answer

Related research questions